DK1663217T3 - Solid dispersions containing tacrolimus - Google Patents

Solid dispersions containing tacrolimus

Info

Publication number
DK1663217T3
DK1663217T3 DK04762795.5T DK04762795T DK1663217T3 DK 1663217 T3 DK1663217 T3 DK 1663217T3 DK 04762795 T DK04762795 T DK 04762795T DK 1663217 T3 DK1663217 T3 DK 1663217T3
Authority
DK
Denmark
Prior art keywords
tacrolimus
release agents
solid dispersions
solid solution
dispersions containing
Prior art date
Application number
DK04762795.5T
Other languages
Danish (da)
Inventor
Per Holm
Tomas Norling
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Priority claimed from PCT/DK2004/000574 external-priority patent/WO2005020994A1/en
Application granted granted Critical
Publication of DK1663217T3 publication Critical patent/DK1663217T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
DK04762795.5T 2003-08-29 2004-08-30 Solid dispersions containing tacrolimus DK1663217T3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301232 2003-08-29
DKPA200301837 2003-12-11
US52979303P 2003-12-15 2003-12-15
DKPA200400079 2004-01-21
DKPA200400463 2004-03-23
DKPA200400467 2004-03-23
PCT/DK2004/000574 WO2005020994A1 (en) 2003-08-29 2004-08-30 Solid dispersions comprising tacrolimus

Publications (1)

Publication Number Publication Date
DK1663217T3 true DK1663217T3 (en) 2010-11-08

Family

ID=42994769

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04762795.5T DK1663217T3 (en) 2003-08-29 2004-08-30 Solid dispersions containing tacrolimus
DK04762794.8T DK1663216T3 (en) 2003-08-29 2004-08-30 Modified release tacrolimus containing compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04762794.8T DK1663216T3 (en) 2003-08-29 2004-08-30 Modified release tacrolimus containing compositions

Country Status (8)

Country Link
US (1) US8591946B2 (en)
JP (1) JP4903568B2 (en)
CN (2) CN1859909B (en)
AT (1) ATE531368T1 (en)
DK (2) DK1663217T3 (en)
ES (1) ES2376238T3 (en)
PT (2) PT1663217E (en)
SI (2) SI1663217T1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663217B1 (en) * 2003-08-29 2010-07-07 LifeCycle Pharma A/S Solid dispersions comprising tacrolimus
KR100678824B1 (en) * 2005-02-04 2007-02-05 한미약품 주식회사 Amorphous tacrolimus solid dispersion with increased solubility and pharmaceutical composition comprising the same
CA2601312A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CA2664641A1 (en) * 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
WO2008084698A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Tacrolimus sustained release pharmaceutical composition
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
CA2680680A1 (en) 2007-03-29 2009-02-19 Panacea Biotec Limited Modified dosage forms of tacrolimus
ES2634153T3 (en) 2007-05-30 2017-09-26 Veloxis Pharmaceuticals A/S Once-daily oral dosage form comprising tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
US8349033B2 (en) * 2007-05-31 2013-01-08 The Penray Companies, Inc. Diesel fuel, diesel fuel additive, and associated method for using the same
CA2700426C (en) 2007-09-25 2017-10-31 Galia Temtsin Krayz Compositions comprising lipophilic active compounds and method for their preparation
CL2008000374A1 (en) 2008-02-05 2008-04-04 Igloo Zone Chile S A PHARMACEUTICAL COMPOSITION THAT INCLUDES A POWDER FOR ORAL SUSPENSION OF TACROLIMUS OR ONE OF ITS SALTS, HYDRATES OR SOLVATOS AND EXCIPIENTS PHARMACEUTICALLY ACCEPTABLE; PROCEDURE FOR PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION; AND USE FOR PREVE
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
RU2574006C2 (en) * 2008-07-08 2016-01-27 Лайфсайкл Фарма А/С Tacrolimus for improved treatment of patients with grafts
KR101174183B1 (en) 2008-11-28 2012-08-16 주식회사 삼양바이오팜 Tacrolimus formulation with enhanced bioavailability and method for manufacturing the same
TWI490209B (en) * 2009-12-07 2015-07-01 雷普特治療有限責任公司 4-methylpyrazole formulations
WO2011080716A2 (en) * 2010-01-04 2011-07-07 Wockhardt Limited Pharmaceutical composition for modified delivery of actives
LT2575769T (en) * 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilized tacrolimus composition
CA2797042A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
US20130102683A1 (en) * 2010-04-22 2013-04-25 Ratiopharm Gmbh Melt-granulated fingolimod
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP6246720B2 (en) * 2011-10-18 2017-12-13 パーデュー、ファーマ、リミテッド、パートナーシップ Acrylic polymer formulation
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
AU2015300798A1 (en) * 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
US20170072058A1 (en) 2014-11-21 2017-03-16 Solipharma Llc Pharmaceutical composition containing tacrolimus and preparation methods thereof
BR112018006406B1 (en) * 2015-10-23 2022-01-18 Basf Se ODORING AND FLAVORING FORMULATION, AND, USE OF A FORMULATION
CN107126419B (en) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 Obeticholic acid tablet and preparation method thereof
CN106309395B (en) * 2016-09-22 2019-09-20 沈阳药科大学 A kind of tacrolimus sustained-release tablet and preparation method thereof
CN107595799A (en) * 2017-10-30 2018-01-19 无锡福祈制药有限公司 A kind of compound enteric-coated oral disintegrating tablet and preparation method thereof
EP3863602A1 (en) * 2018-10-11 2021-08-18 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US20230102590A1 (en) * 2020-02-03 2023-03-30 Senju Pharmaceutical Co., Ltd. Use of polyether compound
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
JP2024508327A (en) 2021-03-03 2024-02-26 サナ バイオテクノロジー，インコーポレイテッド Immunosuppressive therapy in combination with cardiomyocyte therapy, and related methods and compositions
CN114469847B (en) * 2021-12-29 2024-08-13 北京鑫开元医药科技有限公司 Tacrolimus suppository and preparation method and application thereof
CN117049933B (en) * 2023-08-11 2025-02-18 西北大学 A thermoplastic composite tungsten delay agent and its preparation method

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
KR0177158B1 (en) 1990-03-01 1999-03-20 후지사와 도모기찌로 Solutions for inhibition of immune functions containing tricyclic compounds
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
WO1994010981A1 (en) 1992-11-18 1994-05-26 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
ID27825A (en) 1998-03-26 2001-04-26 Fujisawa Pharmaceutical Co SLOW OFF READY
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007842D0 (en) 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
EP1275373A4 (en) 2000-04-17 2007-04-04 Astellas Pharma Inc Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
JP2004503511A (en) 2000-06-12 2004-02-05 スミスクライン・ビーチャム・コーポレイション New solid dispersant composition
US6367913B1 (en) * 2000-10-31 2002-04-09 Hewlett-Packard Company System and method for improving the lightfastness of color printouts
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
CN101961317A (en) * 2001-07-06 2011-02-02 生命周期药物公司 Controlled agglomeration
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
KR100486016B1 (en) 2003-07-09 2005-04-29 주식회사종근당 The solid dispersion and manufacturing process for the rapid dissolution of tacrolimus
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
AU2005219443A1 (en) 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
CA2590675A1 (en) 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
CA2601312A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds

Also Published As

Publication number Publication date
PT1663216E (en) 2012-02-14
ATE531368T1 (en) 2011-11-15
SI1663216T1 (en) 2012-03-30
CN101869561A (en) 2010-10-27
DK1663216T3 (en) 2012-02-20
ES2376238T3 (en) 2012-03-12
SI1663217T1 (en) 2010-10-29
JP4903568B2 (en) 2012-03-28
US20060287352A1 (en) 2006-12-21
CN1859909B (en) 2011-04-06
PT1663217E (en) 2010-10-18
US8591946B2 (en) 2013-11-26
JP2007504103A (en) 2007-03-01
CN1859909A (en) 2006-11-08

Similar Documents

Publication Publication Date Title
DK1663217T3 (en) Solid dispersions containing tacrolimus
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
PL1663216T3 (en) Modified release compositions comprising tacrolimus
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
WO2009090558A3 (en) Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
MX2008000099A (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof.
WO2008071407A3 (en) Coated pellets
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
BRPI0511593A (en) stable formulations during the transition from hydrophobic vehicle to hydrophilic
BG105061A (en) EXTERNALLY COVERED PHARMACEUTICAL COMPOSITION AND METHOD FOR RECEIPT
BRPI0309142C1 (en) suspension of microcapsules in an aqueous liquid phase, which allows the modified release of at least one active ingredient excluding amoxicillin and which is intended to be administered orally
WO2004010984A3 (en) Microcapsules with modified release of active principles with low solubility for oral delivery
NZ610701A (en) Once daily formulation of lacosamide
PL1713446T3 (en) Ternary non-lamellar lipid compositions
AU2603400A (en) Formulations for treating disease and methods of using same
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2007092343A3 (en) Novel epoprostenol formulation and method of making thereof
EE200100433A (en) Pharmaceutical preparation containing clarithromycin, a mixture of fatty and hydrophilic constituents, process for its preparation and use
WO2006085335A3 (en) Pharmaceutical composition of acid labile substances
NO20005838D0 (en) Pharmaceutical multiparticulate form with programmed and controlled release, as well as manufacture thereof
DK1677777T3 (en) Pellets containing venlafaxine hydrochloride
BRPI0011404B8 (en) Extended-release morphine sulfate microgranules, their preparation process and pharmaceutical composition.
WO2005094265A3 (en) Self assembling activation agents targeted using active drug release
ITMI20040498A1 (en) GRANULAR COMPOSITIONS
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use